Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers increased its holdings in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 1.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 111,203 shares of the company’s stock after acquiring an additional 2,093 shares during the period. Rhumbline Advisers owned approximately 0.13% of Verve Therapeutics worth $627,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of VERV. State Street Corp grew its stake in shares of Verve Therapeutics by 27.0% during the 3rd quarter. State Street Corp now owns 4,253,217 shares of the company’s stock worth $20,586,000 after purchasing an additional 903,809 shares during the period. Jacobs Levy Equity Management Inc. grew its position in Verve Therapeutics by 72.2% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,559,393 shares of the company’s stock worth $7,547,000 after buying an additional 653,578 shares during the period. Braidwell LP purchased a new position in Verve Therapeutics in the third quarter valued at about $3,020,000. Ikarian Capital LLC acquired a new stake in shares of Verve Therapeutics during the 3rd quarter valued at approximately $823,000. Finally, Acuta Capital Partners LLC purchased a new stake in shares of Verve Therapeutics during the 3rd quarter worth approximately $707,000. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Stock Performance

Verve Therapeutics stock opened at $6.71 on Friday. Verve Therapeutics, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $16.03. The stock has a fifty day moving average of $6.94 and a two-hundred day moving average of $6.05. The company has a market capitalization of $595.82 million, a price-to-earnings ratio of -2.73 and a beta of 1.77.

Verve Therapeutics (NASDAQ:VERV) last released its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.14. The company had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. On average, analysts forecast that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on VERV. William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Royal Bank of Canada cut their price target on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, HC Wainwright increased their price objective on shares of Verve Therapeutics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Verve Therapeutics presently has an average rating of “Buy” and a consensus target price of $25.50.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.